Last night on Mother & Child with Elena Vasquez
FDA Adds Warning on Rare Vision Loss to GLP-1 Weight-Loss Drugs
The agency is requiring labels on drugs like Ozempic, Wegovy and Zepbound to flag a rare optic nerve condition, even as new studies point to other benefits.
Filed November 10, 2026 · 📍 Washington, DC 20001
Were you there? Share your story
Key points
- The FDA is adding a vision-loss warning to GLP-1 drug labels.
- The condition, NAION, can cause sudden vision loss.
- New Lilly studies explored benefits for sleep apnea and arthritis.
- Patients with sudden vision changes should call a doctor.
Millions of Americans taking popular weight-loss and diabetes drugs will see a new warning on their labels.
The Food and Drug Administration is adding information about possible rare cases of vision loss reported with GLP-1 drugs such as Ozempic, Wegovy and others, CBS News reported [1]. CNBC reported the agency found evidence of a potentially increased risk of a rare eye condition linked to the drugs [2]. NBC News identified the condition as NAION, an optic nerve problem that can cause sudden vision loss and has no known treatment [3]. The Guardian reported the FDA is requiring all GLP-1s to carry the warning [4].
The news comes as research continues to find possible upsides. Time reported that Eli Lilly released results from new studies exploring the effects of its GLP-1 drugs on sleep apnea and arthritis [5].
The takeaway for patients is not panic, it is attention. Anyone on these medications who notices sudden changes in vision should call a doctor right away, and anyone considering them should talk through the risks and benefits with a physician who knows their full history.
Sources
What worries you most about health care?
- Cost
- Getting an appointment
- Quality of care
- Government getting more involved
Were you there?
If you were at the scene, or this story touched your life, tell us what you saw and what it was like.

Discussion 0
Sign in or create a free account to join the discussion.
No comments yet. Start the discussion.